News

AstraZeneca and Daiichi Sankyo’s Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...
US approves AstraZeneca, Daiichi's treatment for lung cancer
AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...
Medical Dialogues11h
AstraZeneca Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...
Zacks Investment Research on MSN2d
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small ...
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...
Fierce Pharma2d
AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset
The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...
pharmaphorum2d
AZ, Daiichi get Datroway nod in lung cancer on second try
AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...
Pharmaceutical Technology on MSN2d
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.
CURE2d
FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have ...